25 February 2015 | News | By BioSpectrum Bureau
Celltrion launches Remisma in 12 EU countries
Remisma treats autoimmune disorders
Singapore: Celltrion Healthcare has announced the launch of Remisma (infliximab) in 12 European markets, namely, Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK.
Remisma, world's first monoclonal antibody to be approved by the European agency is indicated for the treatment of adult and pediatric Crohn's disease (CD), adult and pediatric ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis.
Dr Stanley Hong, president of Celltrion Healthcare, observed, "Autoimmune diseases can have a devastating impact on people's lives and we are proud that Remsima is available for patients across the European Union, offering them a more accessible treatment option to manage their disease."
Dr Antonio LÃ³pez-SanRomÃ¡n, a specialist in Gastroenterology at the University Hospital RamÃ³n y Cajal, Spain said, "Remisma is an effective treatment option and it is encouraging to know that patients across the whole of Europe with diseases like Crohn's and ulcerative colitis now have an additional treatment option. It has already been used successfully around the world, and the availability of biosimilars such as Remsima could help in reducing healthcare spending."